beta-alanine has been researched along with Cerebral Infarction in 4 studies
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| " A second woman with primary APS experienced ischemic arterial strokes and right transverse-sigmoid sinus thrombosis after conversion to rivaroxaban." | 7.80 | Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. ( Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE, 2014) |
| "A 65-year-old man, who had been treated with dabigatran for 66 days prior to electrical cardioversion, developed extensive intestinal, renal and cerebral thromboembolism five days after cardioversion." | 7.79 | [Extensive thromboembolism after cardioversion in a patient treated with dabigatran]. ( Buch, TN; Holm, J; Munck, LK, 2013) |
| "Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF)." | 4.89 | [Evidence of novel oral anticoagulants (NOAC)]. ( Kitazono, T, 2013) |
| " A second woman with primary APS experienced ischemic arterial strokes and right transverse-sigmoid sinus thrombosis after conversion to rivaroxaban." | 3.80 | Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. ( Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE, 2014) |
| "A 65-year-old man, who had been treated with dabigatran for 66 days prior to electrical cardioversion, developed extensive intestinal, renal and cerebral thromboembolism five days after cardioversion." | 3.79 | [Extensive thromboembolism after cardioversion in a patient treated with dabigatran]. ( Buch, TN; Holm, J; Munck, LK, 2013) |
| "dabigatran (Pradaxa®) is a direct and specific thrombin inhibitor." | 2.49 | [General characteristics of the new oral anticoagulants]. ( Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buch, TN | 1 |
| Holm, J | 1 |
| Munck, LK | 1 |
| Kitazono, T | 1 |
| Gegu, M | 1 |
| Chevalet, P | 1 |
| Piloquet, FX | 1 |
| Berrut, G | 1 |
| De Decker, L | 1 |
| Schaefer, JK | 1 |
| McBane, RD | 1 |
| Black, DF | 1 |
| Williams, LN | 1 |
| Moder, KG | 1 |
| Wysokinski, WE | 1 |
2 reviews available for beta-alanine and Cerebral Infarction
| Article | Year |
|---|---|
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta | 2013 |
[General characteristics of the new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabig | 2013 |
2 other studies available for beta-alanine and Cerebral Infarction
| Article | Year |
|---|---|
[Extensive thromboembolism after cardioversion in a patient treated with dabigatran].
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Electric Counter | 2013 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; | 2014 |